Search research articles
Contact Us
Filters
Showing results (521-530 of 532) with videos related to
Page
of 54
Sort By:
Journal of Applied Physiology (Bethesda, Md. : 1985)
|
April 20, 2021
Commentaries on Viewpoint: Differential impact of shear rate in the cerebral and systemic circulation: implications for endothelial function
Jay Carr, Joshua C. Tremblay, Stephen J. Ives, et al.
Journal of the American Academy of Child and Adolescent Psychiatry
|
August 2, 2007
Effects of stimulant medication on growth rates across 3 years in the MTA follow-up
James M Swanson, Glen R Elliott, Laurence L Greenhill, et al.
Journal of the American Academy of Child and Adolescent Psychiatry
|
August 2, 2007
Delinquent behavior and emerging substance use in the MTA at 36 months: prevalence, course, and treatment effects
Brooke S G Molina, Kate Flory, Stephen P Hinshaw, et al.
Communications Biology
|
January 26, 2021
Design and optimisation of dendrimer-conjugated Bcl-2/x<sub>L</sub> inhibitor, AZD0466, with improved therapeutic index for cancer therapy
Claire M Patterson, Srividya B Balachander, Iain Grant, et al.
Molecular Cancer Therapeutics
|
December 4, 2020
AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in <i>KRAS</i>-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib
Vikki Flemington, Emma J Davies, David Robinson, et al.
Journal of Medicinal Chemistry
|
November 12, 2019
Discovery of a Potent and Selective Oral Inhibitor of ERK1/2 (AZD0364) That Is Efficacious in Both Monotherapy and Combination Therapy in Models of Nonsmall Cell Lung Cancer (NSCLC)
Richard A Ward, Mark J Anderton, Paul Bethel, et al.
Nature
|
September 29, 2005
Towards a proteome-scale map of the human protein-protein interaction network
Jean-François Rual, Kavitha Venkatesan, Tong Hao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 29, 2020
AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x<sub>L</sub>, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia
Srividya B Balachander, Steven W Criscione, Kate F Byth, et al.
Nature Communications
|
December 19, 2018
Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia
Adriana E Tron, Matthew A Belmonte, Ammar Adam, et al.
Genome Biology
|
July 22, 2008
A critical assessment of Mus musculus gene function prediction using integrated genomic evidence
Lourdes Peña-Castillo, Murat Tasan, Chad L Myers, et al.
Page
of 54
Search research articles
Search
Showing results (521-530 of 532) with videos related to
Sort By:
Page
of 54
Journal of Applied Physiology (Bethesda, Md. : 1985)
|
April 20, 2021
Commentaries on Viewpoint: Differential impact of shear rate in the cerebral and systemic circulation: implications for endothelial function
Jay Carr, Joshua C. Tremblay, Stephen J. Ives, et al.
Journal of the American Academy of Child and Adolescent Psychiatry
|
August 2, 2007
Effects of stimulant medication on growth rates across 3 years in the MTA follow-up
James M Swanson, Glen R Elliott, Laurence L Greenhill, et al.
Journal of the American Academy of Child and Adolescent Psychiatry
|
August 2, 2007
Delinquent behavior and emerging substance use in the MTA at 36 months: prevalence, course, and treatment effects
Brooke S G Molina, Kate Flory, Stephen P Hinshaw, et al.
Communications Biology
|
January 26, 2021
Design and optimisation of dendrimer-conjugated Bcl-2/x<sub>L</sub> inhibitor, AZD0466, with improved therapeutic index for cancer therapy
Claire M Patterson, Srividya B Balachander, Iain Grant, et al.
Molecular Cancer Therapeutics
|
December 4, 2020
AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in <i>KRAS</i>-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib
Vikki Flemington, Emma J Davies, David Robinson, et al.
Journal of Medicinal Chemistry
|
November 12, 2019
Discovery of a Potent and Selective Oral Inhibitor of ERK1/2 (AZD0364) That Is Efficacious in Both Monotherapy and Combination Therapy in Models of Nonsmall Cell Lung Cancer (NSCLC)
Richard A Ward, Mark J Anderton, Paul Bethel, et al.
Nature
|
September 29, 2005
Towards a proteome-scale map of the human protein-protein interaction network
Jean-François Rual, Kavitha Venkatesan, Tong Hao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 29, 2020
AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x<sub>L</sub>, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia
Srividya B Balachander, Steven W Criscione, Kate F Byth, et al.
Nature Communications
|
December 19, 2018
Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia
Adriana E Tron, Matthew A Belmonte, Ammar Adam, et al.
Genome Biology
|
July 22, 2008
A critical assessment of Mus musculus gene function prediction using integrated genomic evidence
Lourdes Peña-Castillo, Murat Tasan, Chad L Myers, et al.
Page
of 54